IL308068A - A method for dose titration of psychedelics - Google Patents
A method for dose titration of psychedelicsInfo
- Publication number
- IL308068A IL308068A IL308068A IL30806823A IL308068A IL 308068 A IL308068 A IL 308068A IL 308068 A IL308068 A IL 308068A IL 30806823 A IL30806823 A IL 30806823A IL 308068 A IL308068 A IL 308068A
- Authority
- IL
- Israel
- Prior art keywords
- psychedelics
- titrating
- dose
- titrating dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measurement Of Radiation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183579P | 2021-05-03 | 2021-05-03 | |
| PCT/US2022/027179 WO2022235529A1 (en) | 2021-05-03 | 2022-05-01 | Method of titrating dose of psychedelics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308068A true IL308068A (en) | 2023-12-01 |
Family
ID=83932279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308068A IL308068A (en) | 2021-05-03 | 2022-05-01 | A method for dose titration of psychedelics |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4333979A4 (de) |
| JP (2) | JP2024517194A (de) |
| AU (2) | AU2022268891A1 (de) |
| CA (1) | CA3216939A1 (de) |
| IL (1) | IL308068A (de) |
| TW (1) | TW202245767A (de) |
| WO (1) | WO2022235529A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102207640B (zh) * | 2010-03-30 | 2014-05-28 | 比亚迪股份有限公司 | 具有液晶气泡的tft液晶显示器的回收方法 |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| EP4329759A4 (de) | 2021-04-30 | 2025-07-16 | Mind Medicine Inc | Lsd-salzkristallformen |
| US12611399B2 (en) | 2021-05-04 | 2026-04-28 | Definium Therapeutics US, Inc. | Movement disorders |
| KR20240013170A (ko) | 2021-05-25 | 2024-01-30 | 아타이 테라퓨틱스, 인크. | 신규 n,n-디메틸트립타민 염 및 결정질 염 형태 |
| IL309210A (en) | 2021-06-09 | 2024-02-01 | Atai Therapeutics Inc | Parent drugs and conjugates of dimethyltryptamine |
| US20230064429A1 (en) | 2021-08-19 | 2023-03-02 | Mind Medicine, Inc. | IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS |
| EP4387612A4 (de) | 2021-08-20 | 2025-07-23 | Pharmala Biotech Inc | Zusammensetzungen mit nichtracemischen mischungen von (r)- und (s)-3,4-methylendioxymethamphetamin oder (r) und (s) n-methyl-1,3-benzodioxolylbutanamin und verwendungen davon |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10118006B2 (en) * | 2014-06-30 | 2018-11-06 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
| US11723894B2 (en) * | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| MX2021009037A (es) * | 2019-01-30 | 2021-10-13 | Diamond Therapeutics Inc | Composiciones y metodos para el manejo de trastornos. |
| HUE066828T2 (hu) * | 2019-02-22 | 2024-09-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére |
| WO2021003467A1 (en) * | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Metered dosing compositions and methods of use of psychedelic compounds |
-
2022
- 2022-05-01 EP EP22799340.9A patent/EP4333979A4/de active Pending
- 2022-05-01 AU AU2022268891A patent/AU2022268891A1/en not_active Abandoned
- 2022-05-01 WO PCT/US2022/027179 patent/WO2022235529A1/en not_active Ceased
- 2022-05-01 CA CA3216939A patent/CA3216939A1/en active Pending
- 2022-05-01 JP JP2023566881A patent/JP2024517194A/ja active Pending
- 2022-05-01 IL IL308068A patent/IL308068A/en unknown
- 2022-05-03 TW TW111116665A patent/TW202245767A/zh unknown
-
2025
- 2025-08-12 AU AU2025217270A patent/AU2025217270A1/en active Pending
-
2026
- 2026-01-30 JP JP2026014502A patent/JP2026076279A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022268891A1 (en) | 2023-11-09 |
| JP2024517194A (ja) | 2024-04-19 |
| TW202245767A (zh) | 2022-12-01 |
| WO2022235529A1 (en) | 2022-11-10 |
| EP4333979A1 (de) | 2024-03-13 |
| EP4333979A4 (de) | 2025-01-15 |
| CA3216939A1 (en) | 2022-11-10 |
| AU2025217270A1 (en) | 2025-08-28 |
| JP2026076279A (ja) | 2026-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL294214B2 (en) | Cyclic compounds and methods of using same | |
| SG11202113371VA (en) | Method of synthesizing chemical compounds | |
| GB2584946B (en) | Method of selecting ions | |
| GB2590601B (en) | Method of mass spectrometry | |
| IL268479A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| HUE065420T2 (hu) | Eljárás ciklikus kulometriára | |
| GB201804594D0 (en) | Bonegraft substituteand method of manufacture | |
| GB201900971D0 (en) | Insole apparatus and method of manufacture thereof | |
| SG10202003054XA (en) | Manufacturing method of chips | |
| IL287210A (en) | Preparations for the treatment of tumors | |
| GB2553390B (en) | Method of manufacture | |
| GB201802839D0 (en) | Method of manufacture | |
| IL287250A (en) | treatment method | |
| IL289811A (en) | A method for treating cancer | |
| SG10202007717QA (en) | Manufacturing method of packages | |
| GB201903055D0 (en) | Method of oligonucleaotide synthesis | |
| GB201704816D0 (en) | Method of manufacture | |
| ES3065882T3 (en) | Method of haplotyping | |
| GB201905379D0 (en) | Method of epoxidation | |
| GB202106258D0 (en) | Method of formulation | |
| ZA201903823B (en) | Method of encapsulation | |
| GB202006949D0 (en) | Method of formulation | |
| GB201906748D0 (en) | Method of formulation | |
| GB202102950D0 (en) | Method of treatment | |
| GB202018243D0 (en) | Method of treatment |